{"pageContent": "Prostate-specific membrane antigen (PSMA)-based radioguidance for salvage lymph node dissection (sLND) in recurrent prostate cancer has shown promising early oncological outcomes. However, long-term outcomes are still undetermined. Future studies are needed before introducing PSMA positron emission tomography-based sLND into routine clinical practice outside of clinical trials or registries.", "metaData": {"source": "Prostate cancer proteomics\nhttps://pubmed.ncbi.nlm.nih.gov/21319990/"}}